The activity of SGLT2 inhibitors is independent of insulin status, meaning their efficacy is not diminished by insulin resistance or absolute insulin deficiency, making them suitable for use in both Type 2 and Type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.